Helicobacter pylori, acid, and omeprazole revisited: Bacterial eradication and rebound hypersecretion

Gastroenterology

Volumn 116, Issue 2, 1999, Pages 479-483

  Kuipers, E J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; DRUG EFFICACY; EDITORIAL; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH ANTRUM; STOMACH MUCOSA; STOMACH PH;

EID: 0032931191     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70145-9     Document Type: Editorial

References (35)

1. M Rektorschek D Weeks G Sachs K. Melchers Influence of pH on metabolism and urease activity of Helicobacter pylori Gastroenterology 115 1998 628 641
2. E Solcia I Villani R Fiocca O Luinetti R Boldorini E Trespi M Perego C Alvisi M Lazzaroni G. Bianchi Porro Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients Scand J Gastroenterol 29 suppl 201 1994 28 34
3. T Lind SJO Veldhuyzen van Zanten P Unge R Spiller E Bayerdörffer C O'Morain KD Bardhan M Bradette N Chiba M Wrangstadh C Cederberg JP. Idström The MACH-1 study optimal one-week treatment for H. pylori defined? Helicobacter 1 1996 138 144
4. KEL McColl L Murray E El-Omar A Dickson A El-Nujumi A Wirz A Kelman C Penny R Knill-Jones T. Hilditch Symptomatic benefit from eradicating Helicobacter pylori infection in non-ulcer dyspepsia N Engl J Med 339 1998 1869 1874
5. T Lind F Mégraud P Unge E Bayerdörffer C O'Morain R Spiller SJO Veldhuyzen van Zanten KD Bardhan M Hellblom M Wrangstadh L Zeijlon C. Cederberg The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies Gastroenterology 116 1999 248 253
6. A Goodwin D Kersulyte G Sisson SJO Veldhuyzen van Zanten DE Berg PS. Hoffman Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene ( rdxA ) that encodes an oxygen-intensive NADPH nitroreductase Mol Microbiol 28 1998 383 393
7. YJ Debets-Ossenkopp M Sparius JG Kusters JJ Kolkman CMJE Vandenbroucke-Grauls Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori FEMS Microbiol Lett 142 1996 37 42
8. YJ Debets-Ossenkopp AB Brinkman EJ Kuipers CMJE Vandenbroucke-Grauls JG. Kusters Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori Antimicrob Agents Chemother 42 1998 2749 2751
9. MJ Buckley HX Xia DM Hyde CT Keane CA. O'Morain Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance Dig Dis Sci 42 1997 2111 2115
10. AA van Zwet CMJE Vandenbroucke-Grauls JC Thijs EJ van der Wouden MM Gerrits JG. Kusters Stable amoxycillin resistance in Helicobacter pylori Lancet 352 1998 1595
11. L Laine L Suchower J Frantz A Connors G. Neil Twice-daily, 10-day triple therapy with omeprazole, amoxycillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials Am J Gastroenterol 93 1998 2106 2112
12. F Catalaro R Catanzaro C Bentivegna A Brogna G Condorelli R. Cipolla Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer Aliment Pharmacol Ther 12 1998 59 62
13. JY Sung WK Leung TKW Ling MJ Yung FKL Chan YT Lee AFB Cheng SCS. Chung One-week ranitidine bismuth citrate (RBC) triple therapy versus proton-pump inhibitor (PPI) triple therapy for the treatment of H. pylori -associated duodenal ulcers Aliment Pharmacol Ther 12 1998 725 730
14. EJ van der Wouden JC Thijs AA van Zwet A Kooy JH. Kleibeuker One week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori: a randomized clinical trial Am J Gastroenterol 93 1998 1228 1231
15. W de Boer W Driessen A Jansz GNJ. Tytgat Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection Lancet 345 1995 817 820
16. E El-Omar I Penman JES Ardill KEL. McColl A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients Gut 36 1995 534 538
17. D Gillen M. E-OE AA Wirtz JES Ardill KEL. McColl The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori -infected healthy subjects Gastroenterology 114 1998 50 57
18. O Gutierrez M Melo AM Segura A Angel RM Genta DY. Graham Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis Scand J Gastroenterol 32 1997 664 668
19. B Ruiz P Correa ETH Fontham T. Ramakrishnan Antral atrophy, Helicobacter pylori colonization, and gastric pH Am J Clin Pathol 105 1996 96 101
20. GV Rohrer JD. Welsh Correlative study: gastric secretion and histology Gastroenterology 52 1967 185 191
21. EM El-Omar K Oien A El-Nujumi D Gillen A Wirz S Dahill C Williams JES Ardill KEL. McColl Helicobacter pylori infection and chronic acid hyposecretion Gastroenterology 113 1997 15 24
22. MJ. Blaser Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era Gut 43 1998 721 727
23. JE Richter GW Falk MF. Vaezi Helicobacter pylori and gastroesophageal reflux disease: the bug may not all be bad Am J Gastroenterol 10 1998 1800 1802
24. E Verdú D Armstrong R Fraser F Viani J-P Idström C Cederberg AL. Blum Effect of H. pylori status on intragastric pH during treatment with omeprazole Gut 36 1995 539 543
25. BE Schenk EJ Kuipers EC Klinkenberg-Knol SA Eskes SGM. Meuwissen H. pylori and the efficacy of omeprazole for gastroesophageal reflux disease Am J Gastroenterol 1999 (in press)
26. EC. Klinkenberg-Knol Eleven years experience of continuous maintenance treatment with omeprazole in GERD patients (abstr) Gastroenterology 114 1998 A180
27. FTM Peters EJ Kuipers S Ganesh WJ Sluiter EC Klinkenberg-Knol CBHW Lamers JH. Kleibeuker Helicobacter pylori and esophageal acid exposure in GERD (abstr) Gastroenterology 114 1998 A257
28. G Holtmann C Cain P. Malfertheiner Helicobacter pylori accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole (abstr) Gastroenterology 114 1998 A151
29. D Gillen AA Wirz JE Ardill KEL. McColl Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status Gastroenterology 116 1999 239 247
30. GJB Hurenkamp HGLM Grundmeyer PJE Bindels GNJ Tytgat RWM. van der Hulst A population-based inventarisation of longterm acid suppressant use in 24 general practices in the Netherlands Digestion 59 suppl 3 1998 101
31. 2 receptor antagonist Gut 30 1989 449 454
32. HL Waldum JS Arnestad E Brenna I Eide U Syversen AK. Sandvik Marked increase in gastric acid secretory capacity after omeprazole treatment Gut 29 1996 649 653
33. DK Driman C Wright G Tougas RH. Riddell Omeprazole produces parietal cell hypertrophy and hyperplasia in humans Dig Dis Sci 41 1996 2039 2047
34. Cats A, Bloemena E, Schenk BE, Lindeman J, Klinkenberg-Knol EC, Meuwissen SGM, Kuipers EJ. Parietal cell protrusion (PCP) and fundic gland cysts (FGC) in GERD in relation to omeprazole and H. pylori (abstr). Gastroenterology (submitted).
35. PO Katz C Anderson R Khoury DO. Castell Gastro-oesophageal reflux associated with nocturnal breakthrough on proton pump inhibitors Aliment Pharmacol Ther 12 1998 1231 1234